XML 16 R2.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Mar. 31, 2023
Current assets:    
Cash and cash equivalents $ 75,996 $ 146,590
Short-term investments 420,765 436,796
Research and development incentives receivable 2,900 2,939
Prepaid expenses and other current assets 8,514 6,278
Total current assets 508,175 592,603
Property, plant and equipment, net 8,445 7,479
Research and development incentives receivable, non-current 809 0
Restricted cash 1,636 1,636
Right-to-use asset - operating leases 4,882 5,208
Right-to-use asset - financing leases 38,451 39,665
Total assets 562,398 646,591
Current liabilities:    
Accounts payable 4,365 5,364
Accrued expenses and other current liabilities 31,651 24,704
Operating lease liabilities, current 1,138 1,118
Financing lease liabilities, current 2,678 2,639
Total current liabilities 39,832 33,825
Operating lease liabilities, non-current 4,052 4,389
Financing lease liabilities, non-current 23,709 23,965
Long term debt, net of discount 29,161 28,648
Other liabilities, non-current 472 472
Total liabilities 97,226 91,299
Commitments and contingencies (Note 14)
Stockholders' equity    
Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30, 2023 and March 31, 2023; 59,059,343 and 56,676,313 shares issued and outstanding as of September 30, 2023 and March 31, 2023, respectively 59 57
Additional paid-in capital 1,054,712 1,034,994
Accumulated deficit (595,087) (485,488)
Accumulated other comprehensive income 5,488 5,729
Total stockholders' equity 465,172 555,292
Total liabilities and stockholders' equity $ 562,398 $ 646,591